How Long Do Biomarker Results Take — and Why the Wait?

Most single-marker tests such as PD-L1 immunohistochemistry are typically reported in 2 to 4 working days, and MSI testing by immunohistochemistry in about 3 to 5 days. Broader next-generation sequencing (NGS) panels that report tumour mutational burden (TMB) alongside multiple gene mutations commonly take 7 to 14 working days, occasionally longer if a sample needs repeat processing.

Exactly where your report falls within that range depends on which test was ordered, how the coordinating laboratory batches its runs, and how much usable tissue your original sample provided. A well-preserved surgical specimen is usually faster to process than a small needle-biopsy sample that needs to be handled carefully to make it stretch across every ordered test.

These are commonly cited laboratory windows, indicative as of August 2026, not a fixed promise for your specific sample — your oncology team or the coordinating lab can confirm exactly where your own report stands.

Ranges shown are commonly cited laboratory windows, indicative as of August 2026, and vary by lab, batching schedule and sample quality — not a guarantee for your specific report.

1. 1

   Sample transport and accessioning

   The sample reaches the coordinating laboratory, is logged in, and is checked to confirm there is enough usable tissue for the tests ordered.

2. 2

   Tissue processing

   Thin sections are cut from the sample for staining tests, or tissue is set aside for DNA/RNA extraction if a molecular test is also ordered.

3. 3

   Test-specific processing

   This is where tests diverge most — an IHC stain, a PCR run, or a full NGS library-preparation-and-sequencing run, each with a different processing time.

4. 4

   Analysis and quality control

   Results are checked against internal controls; a borderline or unclear result can trigger a repeat run before it is finalised.

5. 5

   Pathologist or molecular sign-off

   A qualified pathologist or molecular pathologist reviews and formally signs the report — the step that makes it a clinical result, not a raw data point.

6. 6

   Report reaches your oncology team

   The signed report is shared with your treating oncologist and, where relevant, discussed at your tumour board before your next consultation.

Sometimes, but this is never automatic. Whether any treatment begins before a biomarker report returns is a case-by-case decision made by your oncology team, weighed against how clinically urgent treatment is, which specific markers are still pending, and whether the delay itself carries a meaningful risk.

In many situations, oncologists prefer to wait for the markers that decide the first-line regimen — starting the wrong combination first can close off better options later. In more urgent presentations, a treatment that does not depend on the pending marker may begin while biomarker-directed therapy is planned in parallel, or a multidisciplinary tumour board may weigh starting against waiting, one patient at a time rather than by one fixed rule.

This page cannot tell you whether it is appropriate to start treatment before your specific report returns — that decision belongs to your treating oncologist, looking at your cancer, stage and overall health together.

• Confirm sample status — ask the coordinating lab or your care team whether the sample was received and accessioned, so at least the starting point of the clock is clear.
• Complete other pre-treatment steps — staging scans, cardiac and pulmonary fitness checks, and pre-treatment counselling can usually continue in parallel.
• Prepare questions for your oncologist — writing concerns down in advance makes the consultation once results arrive focused, not rushed.
• Loop in your support person — a spouse or family caregiver tracking dates and follow-ups reduces the mental load of a numbers-heavy wait.
• Be cautious of "boosting" claims — no product, supplement or practice speeds up a laboratory's turnaround time; treat any claim otherwise with scepticism.

These steps manage the wait — they do not change how quickly a laboratory can process a sample.

• Not Enough Tissue for Testing: What Happens Next — one common reason a report is delayed or a repeat sample is needed.
• Do You Need a Repeat Biopsy Before Starting Immunotherapy? — what happens when the original sample can't answer every question.
• Genetic and Genomic Reports: Reading the Summary Page — once your report arrives, how to follow what it actually says.
• Immunotherapy at CION Cancer Clinics — the full picture of how CION supports patients through testing, eligibility and treatment.

This page explains general turnaround-time information for education only and does not track or interpret any individual patient's report. Testing is coordinated at accredited partner laboratories — contact your care team directly for the status of your own sample.

Thousands of families have waited through this exact stage

A pending report can feel like the whole plan is on hold. Our oncologists keep you informed and keep every other preparation moving while you wait.